Preclinical studies consistently show EpCAM CAR-T cells inhibit tumor progression in animal models of colorectal cancer [20–24], gastric cancer [25–27], prostate cancer [28] and ovarian cancer [20, 29]. Here, EPCAM is linked to neoplasm.